title: Impact of HLA-identity on results of ABO-incompatible living kidney transplantation.
abstract: BACKGROUND
  Due to the continuing shortage of cadaveric donors in Japan, ABO-incompatible living kidney transplantation is being performed. Our previous studies showed that the long-term graft survival in ABO-incompatible living kidney transplantation was comparable to that in ABO-compatible living kidney transplantation. However, the impact on HLA-identity on the results of ABO-incompatible living donor kidney transplantation had not been investigated previously.
  
  
  METHODS
  One hundred twenty-seven recipients underwent ABO-incompatible living kidney transplantation between January 1989 and December 2000. Five were grafted from HLA-identical sibling donors group (I). The remaining 122 recipients received grafts from an HLA-nonidentical donor (group N). Both groups were similar in terms of recipient age, donor age, warm ischemic time, and total ischemic time. Three or four sessions of plasmapheresis were performed prior to transplantation. Cyclosporine or tacrolimus, methylprednisolone, and azathioprine or mycophenolate mofetil were used for immunosuppression. Splenectomy was done at the time of kidney transplantation in all patients.
  
  
  RESULTS
  Graft loss was seen in one of the five HLA-identical recipients due to chronic rejection. Five- and 10-year graft survival rates were 80.0% I vs 72.0% N, and 80.0% I vs 54.2% N, respectively. The incidence of acute rejection in the HLA-identical recipients was lower than that in the HLA-nonidentical recipients (20% I vs 67.2% N). In conclusion, long term graft survival among ABO-incompatible kidney transplants from HLA-identical sibling donors was much better than that from HLA-nonidentical sibling donors.
authors.affiliation: Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. shimmura@kc.twmu.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Shimmura
authors.forename: K
authors.initials: K
authors.lastname: Tanabe
authors.forename: T
authors.initials: T
authors.lastname: Tokumoto
authors.forename: H
authors.initials: H
authors.lastname: Ishida
authors.forename: N
authors.initials: N
authors.lastname: Ishikawa
authors.forename: N
authors.initials: N
authors.lastname: Miyamoto
authors.forename: T
authors.initials: T
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Shirakawa
authors.forename: K
authors.initials: K
authors.lastname: Setoguchi
authors.forename: S
authors.initials: S
authors.lastname: Teraoka
authors.forename: H
authors.initials: H
authors.lastname: Toma
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000328:Adult; D001787:Blood Group Incompatibility; D005260:Female; D006085:Graft Survival / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D035781:Siblings; D016019:Survival Analysis
chemical_list: D000017:ABO Blood-Group System